Drug giant sours on Mayne Pharma deal

A US drug company has threatened to walk away from a deal to acquire Australian-owned Mayne Pharma over a disagreement about whether a “material adverse change” happened ASX-listed Mayne Pharma saw its share price drop by 30% in Wednesday’s trade after its suitor, Cosette Pharmaceuticals, raised concerns about its financial position. Mayne received a $672m